TABLE 1.
Baseline patient characteristics of propensity score matched patients
| Characteristics n (%) or mean (±SD) |
History of hypertension | No history of hypertension | |||||
|---|---|---|---|---|---|---|---|
| Placebo (n=1838) |
Eplerenone (n=1838) |
P value |
Placebo (n=1176) |
Eplerenone (n=1176) |
P value | ||
| Age, y* | 65.5 (±11) | 65.4 (±11) | 0.654 | 61.7 (±13) | 61.8 (±12) | 0.859 | |
| Age ≥65 y* | 1032 (56) | 1010 (55) | 0.486 | 500 (43) | 502 (42) | 0.934 | |
| Women* | 634 (35) | 623 (24) | 0.702 | 248 (21) | 244 (21) | 0.879 | |
| Nonwhites | 177 (10) | 185 (10) | 0.698 | 115 (10) | 119 (9) | 0.674 | |
| Smoking status* | |||||||
| Current | 453 (25) | 461 (25) | 0.895 | 471 (40) | 464 (40) | 0.957 | |
| Never | 836 (46) | 822 (45) | 354 (30) | 357 (30) | |||
| Former | 549 (30) | 555 (30) | 351 (30) | 355 (30 | |||
| Medical history | |||||||
| AMI* | 545 (30) | 543 (30) | 0.971 | 277 (24) | 278 (23) | 1.000 | |
| Angina* | 881 (48) | 893 (49) | 0.717 | 357 (30) | 363 (21) | 0.823 | |
| HF* | 322 (18) | 319 (17) | 0.896 | 117 (10) | 119 (10) | 0.891 | |
| Prior HF hospitalization* | 161 (9) | 159(9) | 0.953 | 68 (6) | 66 (6) | 0.859 | |
| Diabetes* | 685 (37) | 689 (38) | 0.919 | 288 (25) | 288 (25) | 1.000 | |
| Killip status* | |||||||
| I | 294 (16) | 308 (17) | 0.928 | 179 (15) | 174 (15) | 0.964 | |
| II | 1157 (63) | 1152 (63) | 790 (67) | 799 (68) | |||
| III | 332 (18) | 323 (18) | 167 (14) | 161 (14) | |||
| IV | 55 (3) | 55 (3) | 40 (3) | 42 (4) | |||
| Medications | |||||||
| ACEIs* | 1584 (86) | 1585 (86) | 1.000 | 966 (82) | 964 (82) | 0.957 | |
| ARBs | 60 (3) | 63 (3) | 0.855 | 32 (3) | 32 (3) | 1.000 | |
| Beta-blockers | 1364 (74) | 1370 (75) | 0.850 | 886 (75) | 886 (75) | 1.000 | |
| Alpha-blockers* | 49 (3) | 46 (3) | 0.757 | 8 (1) | 7 (1) | 0.803 | |
| Calcium channel blockers* | 356 (19) | 356 (19) | 1.000 | 127 (11) | 128 (11) | 1.000 | |
| Glycoprotein IIb/IIIa blockers | 14 (1) | 18 (1) | 0.595 | 10 (1) | 10 (1) | 1.000 | |
| Antiarrhythmic drugs | 230 (13) | 221 (12) | 0.651 | 126 (11) | 129 (11) | 0.843 | |
| Antiplatelet drugs* | 464 (25) | 469 (26) | 0.880 | 402 (34) | 394 (34) | 0.760 | |
| Anticoagulants* | 339 (18) | 327 (18) | 0.638 | 173 (15) | 171 (15) | 0.953 | |
| Aspirin | 1640 (89) | 1640 (89) | 1.000 | 1037 (88) | 1039 (88) | 0.949 | |
| Statins* | 798 (43) | 809 (44) | 0.740 | 595 (51) | 596 (51) | 0.997 | |
| Other lipid-lowering agents | 31 (2) | 34 (2) | 0.803 | 16 (1) | 16 (1) | 1.000 | |
| Digoxin† | 296 (16) | 290 (16) | 0.787 | 159 (14) | 160 (14) | 0.952 | |
| Nitrates* | 1232 (67) | 1223 (67) | 0.753 | 651 (55) | 652 (55) | 1.000 | |
| Loop diuretics* | 1069 (58) | 1068 (58) | 1.000 | 593 (50) | 595 (51) | 0.967 | |
| Other diuretics* | 176 (10) | 168 (9) | 0.692 | 66 (6) | 65 (6) | 1.000 | |
| Potassium supplements | 322 (18) | 309 (17) | 0.570 | 180 (15) | 180 (15) | 1.000 | |
| Magnesium supplements | 77 (4) | 76 (4) | 1.000 | 40 (3) | 36 (3) | 0.643 | |
| Body mass index, kg/m2* | 28 (±5) | 28 (±4) | 0.812 | 27 (±4) | 26 (±4) | 0.738 | |
| Blood pressure, mm Hg | |||||||
| Systolic* | 123 (±17) | 123 (±17) | 0.894 | 114 (±14) | 113 (±15) | 0.795 | |
| Diastolic* | 74 (±11) | 74 (±11) | 0.997 | 70 (±10) | 70 (±10) | 0.934 | |
| Heart rate per minute | 74 (±11) | 74 (±11) | 0.762 | 75 (±12) | 75 (±12) | 0.822 | |
| LVEF, %† | 33 (±6) | 33 (±6) | 0.767 | 33 (±6) | 33 (±6) | 0.735 | |
| Serum concentrations, mean | |||||||
| Sodium, mmol/L* | 140 (±4) | 140 (±5) | 0.850 | 139 (±4) | 139 (±4) | 0.610 | |
| Potassium, mmol/L* | 4.3 (±0.5) | 4.3 (±0.5) | 0.949 | 4.3 (±0.4) | 4.3 (±0.4) | 0.567 | |
| Creatinine, mg/dL* | 1.16 (±0.4) | 1.15 (±0.3) | 0.784 | 1.09 (±0.4) | 1.09 (±0.3) | 0.949 | |
*
indicates P<0.0001;
†
P<0.05 for significant difference between patients with and without a history of hypertension.
ACEI indicates angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; HF, heart failure, LVEF, left ventricular ejection fraction.